| Literature DB >> 30292239 |
Joachim Gæde1, Trine Nielsen1, Mia L Madsen1, Ulla Toft2, Torben Jørgensen2,3,4, Kim Overvad5, Anne Tjønneland5, Torben Hansen1, Kristine H Allin1,6, Oluf Pedersen7.
Abstract
BACKGROUND: It has been suggested that the acidity of the diet may be related to increased risk of type 2 diabetes. To investigate this hypothesis, we tested if the acidity of the diet, measured as the Potential Renal Acid Load (PRAL) score, was associated with incident diabetes and diabetes-related intermediary traits.Entities:
Keywords: Dietary acid load; Disposition index; Glucose; Insulin resistance; PRAL; Type 2 diabetes
Mesh:
Year: 2018 PMID: 30292239 PMCID: PMC6173920 DOI: 10.1186/s12937-018-0395-1
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Baseline characteristics of study participants in the Inter99 study and in the DCH cohort by quintiles of PRAL score
| Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Total | |
|---|---|---|---|---|---|---|
| Inter99 ( | ||||||
| Participants, n | 1127 | 1126 | 1126 | 1126 | 1126 | 5631 |
| PRAL range, mEq/d | −92; − 13 | −13; − 3 | −3; 4 | 4; 12 | 12; 90 | −92; 90 |
| Men, n (%) | 469 (42) | 530 (47) | 487 (43) | 581 (52) | 722 (64) | 2789 (50) |
| Age, years | 50 (41; 55) | 50 (40; 55) | 45 (40; 50) | 45 (40; 50) | 45 (40; 50) | 45 (40; 50) |
| BMI, kg/m2 | 26.2 ± 4.5 | 26.1 ± 4.4 | 26.1 ± 4.6 | 26.1 ± 4.3 | 26.3 ± 4.6 | 26.2 ± 4.5 |
| Physical activity, min/week (%) | ||||||
| 0–112 | 117 (10) | 136 (12) | 133 (12) | 157 (14) | 155 (14) | 698 (12) |
| 142.5–225 | 246 (22) | 248 (22) | 261 (23) | 256 (23) | 256 (23) | 1267 (23) |
| 255–420 | 601 (53) | 586 (52) | 609 (54) | 573 (51) | 571 (51) | 2940 (52) |
| 450–720 | 163 (14) | 156 (14) | 123 (11) | 140 (12) | 144 (13) | 726 (13) |
| Smoking, n (%) | ||||||
| Current | 539 (48) | 444 (39) | 420 (37) | 390 (35) | 396 (35) | 2189 (39) |
| Former | 283 (25) | 304 (27) | 292 (26) | 287 (25) | 267 (24) | 1433 (25) |
| Never | 305 (27) | 378 (34) | 414 (37) | 449 (40) | 463 (41) | 2009 (36) |
| Energy intake, KJ/d | 9286 ± 3082 | 9043 ± 2878 | 9049 ± 2861 | 9605 ± 2866 | 11,039 ± 3163 | 9604 ± 3064 |
| Protein, g/d | 76 ± 23 | 77 ± 23 | 79 ± 23 | 85 ± 23 | 103 ± 28 | 84 ± 26 |
| Carbohydrates, g/d | 293 ± 114 | 268 ± 96 | 263 ± 93 | 274 ± 92 | 302 ± 98 | 280 ± 100 |
| Dietary fiber, g/d | 23 ± 11 | 21 ± 8 | 20 ± 8 | 21 ± 8 | 23 ± 9 | 22 ± 9 |
| Fat intake total, g/d | 67 (51; 88) | 72 (56; 94) | 76 (59; 98) | 84 (66; 107) | 103 (79; 132) | 80 (60; 105) |
| Saturated fat, g/d | 25 (18; 35) | 28 (21; 38) | 29 (22; 39) | 33 (25; 43) | 40 (30; 53) | 31 (22; 42) |
| Diet, Cancer and Health ( | ||||||
| Participants, n | 10,931 | 10,930 | 10,930 | 10,930 | 10,930 | 54,651 |
| PRAL range, mEq/d | − 117; −10 | −10; −3 | −3; 4 | 4; 12 | 12; 89 | −117; 89 |
| Men, n (%) | 3564 (33) | 4215 (39) | 4838 (44) | 5789 (53) | 7402 (68) | 25,808 (47) |
| Age, years | 55 (52; 60) | 56 (52; 60) | 56 (52; 60) | 56 (52; 60) | 55 (52; 60) | 56 (52; 60) |
| BMI, kg/m2 | 25.6 ± 3.9 | 25.8 ± 4.0 | 26.0 ± 3.9 | 26.1 ± 4.0 | 26.4 ± 4.1 | 26.0 ± 4.0 |
| Physical activity, MET-h/week | 59 (39; 88) | 56 (37; 84) | 56 (36; 82) | 56 (37; 83) | 57 (37; 87) | 57 (37; 85) |
| Smoking, n (%) | ||||||
| Current | 4551 (42) | 4203 (38) | 3723 (34) | 3615 (33) | 3605 (33) | 15,713 (29) |
| Former | 2963 (27) | 2948 (27) | 3125 (29) | 3287 (30) | 3390 (31) | 19,697 (36) |
| Never | 3417 (31) | 3779 (35) | 4082 (37) | 4028 (37) | 3935 (36) | 19,241 (35) |
| Energy intake, KJ/d | 9013 ± 2463 | 9026 ± 2405 | 9374 ± 2432 | 9948 ± 2467 | 11,384 ± 2745 | 9749 ± 2657 |
| Protein, g/d | 82 ± 23 | 86 ± 23 | 91 ± 23 | 99 ± 24 | 119 ± 29 | 95 ± 28 |
| Carbohydrates, g/d | 254 ± 78 | 240 ± 71 | 243 ± 70 | 252 ± 70 | 276 ± 75 | 253 ± 74 |
| Dietary fiber, g/d | 22 ± 8 | 20 ± 7 | 20 ± 7 | 20 ± 6 | 22 ± 7 | 21 ± 7 |
| Fat intake total, g/d | 67 (53; 83) | 73 (58; 89) | 78 (64; 96) | 86 (70; 105) | 104 (86; 126) | 81 (64; 101) |
| Saturated fat, g/d | 25 (19; 32) | 28 (22; 35) | 30 (24; 37) | 33 (27; 41) | 40 (33; 49) | 31 (24; 39) |
| Food intake, g/d | ||||||
| Red meat | 63 (46; 84) | 70 (52; 93) | 77 (57; 101) | 85 (63; 112) | 105 (75; 141) | 78 (56; 107) |
| Fish | 32 (21; 46) | 35 (23; 49) | 37 (25; 52) | 41 (28; 57) | 49 (33; 70) | 38 (25; 55) |
| Dairy products | 263 (121; 515) | 278 (138; 536) | 289 (152; 547) | 307 (172; 576) | 344 (206; 617) | 295 (156; 560) |
| Vegetables | 180 (113; 272) | 158 (100; 223) | 151 (99; 213) | 148 (97; 207) | 155 (104; 213) | 157 (102; 224) |
| Fruit | 202 (107; 350) | 154 (81; 254) | 141 (74; 224) | 131 (68; 204) | 117 (61; 189) | 145 (75; 240) |
Data are mean ± standard deviation or median (inter quartile range) unless otherwise specified. Descriptive data on the Inter99 cohort are on non-diabetic individuals only. MET Metabolic Equivalent of Task, PRAL Potential Renal Acid Load
Fig. 1Hazard ratio (HR) of incident diabetes according to PRAL score quintiles in the full DCH cohort. Age is used as the time scale in the cox model. Model 1 is adjusted for fat, energy and carbohydrate intake, smoking and physical activity, while model 2 is adjusted for BMI, fat, energy and carbohydrate intake, smoking and physical activity. Squares indicate HR for model 1, and circles indicate HR for model 2. The p-value shown indicates significance of a trend test
Fig. 2Hazard ratio (HR) of incident diabetes according to PRAL score quintiles in the DCH cohort stratified by sex. Age is used as the time scale in the cox model. Model 1 is adjusted for fat, energy and carbohydrate intake, smoking and physical activity, while model 2 is adjusted for BMI, fat, energy and carbohydrate intake, smoking and physical activity. Squares indicate HR for model 1, and circles indicate HR for model 2. The p-value shown indicates significance of a trend test
Fig. 3PRAL score and glucose tolerance status among participants of the Inter99 study. Odds ratios (OR) of impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes (T2D) according to PRAL score as shown for one standard deviation of PRAL score in the total population (16.36 mEq/day). Model 1 is adjusted for age, sex, smoking, physical activity and fat, energy and carbohydrate intake, while model 2 is adjusted for age, sex, BMI, smoking, physical activity and fat, energy and carbohydrate intake. NGT = Normal Glucose Tolerance. Participants having combined IFG and IGT were classified as IGT. Squares indicate OR for model 1, and circles indicate OR for model 2
Associations between PRAL score and diabetes-related intermediary traits in the baseline part of Inter99 study as well as means and medians for the individual quintiles
| Variable | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | BetaModel 1 (95%CI) |
|
|
|---|---|---|---|---|---|---|---|---|
| PRAL range (mEq/d) | −92; −13 | −13; −3 | −3; 4 | 4; 12 | 12; 90 | |||
| HBA1C (%)a | 5.9 ± 0.5 | 5.8 ± 0.5 | 5.8 ± 0.5 | 5.8 ± 0.6 | 5.8 ± 0.5 | −0.0009 (−0.002; −5 × 10−5) | 0.04 | 0.01 |
| Plasma glucose (mmol/l) | ||||||||
| Fastinga | 5.6 ± 0.8 | 5.5 ± 0.8 | 5.5 ± 0.6 | 5.6 ± 0.9 | 5.5 ± 0.9 | − 0.0003 (− 0.002; 0.001) | 0.7 | 0.2 |
| 30 mina | 8.7 ± 2.0 | 8.7 ± 1.9 | 8.6 ± 1.9 | 8.6 ± 1.8 | 8.7 ± 1.8 | − 0.0009 (− 0.004; 0.002) | 0.6 | 0.2 |
| 120 min | 5.7 (4.8; 6.9) | 5.9 (4.9; 6.9) | 5.9 (4.9; 6.9) | 6.0 (5.0; 7.0) | 5.9 (5.0; 7.0) | 0.2 (0.1; 0.2) | 4 × 10−10 | 1 × 10−8 |
| Serum insulin (pmol/l) | ||||||||
| Fasting | 32 (22; 47) | 33 (23; 50) | 36 (24; 52) | 35 (25; 53) | 36 (25; 53) | 0.2 (0.09; 0.3) | 2 × 10−4 | 0.008 |
| 30 min | 239 (171; 334) | 234 (165; 346) | 243 (181; 349) | 257 (178; 376) | 257 (183; 368) | 0.07 (− 0.03; 0.2) | 0.2 | 0.8 |
| 120 min | 145 (86; 230) | 151 (96; 246) | 164 (103; 253) | 162 (103; 273) | 162 (95; 273) | 0.6 (0.4; 0.7) | 8 × 10−16 | 6 × 10−14 |
| Measures of beta cell function | ||||||||
| Insulinogenic index | 24.2 (16.5; 35.4) | 23.4 (15.9; 34.7) | 24.7 (17.2; 36.3) | 25.8 (17.2; 38.8) | 25.4 (17.2; 37.5) | 0.06 (−0.06; 0.2) | 0.3 | 0.8 |
| Corrected insulin response | 638 (392; 1051) | 602 (392; 1033) | 689 (413; 1107) | 691 (410; 1146) | 679 (413; 1094) | 0.09 (−0.04; 0.2) | 0.2 | 0.3 |
| Measures of insulin sensitivity | ||||||||
| HOMA-IR | 1.3 (0.89; 2.0) | 1.3 (0.89; 2.1) | 1.4 (0.94; 2.2) | 1.4 (0.98; 2.2) | 1.4 (0.97; 2.2) | 0.2 (0.07; 0.3) | 0.001 | 0.04 |
| ISIMatsuda | 8.4 (5.6; 11.7) | 8.1 (5.3; 11.9) | 7.8 (5.1; 11.1) | 7.5 (5.1; 10.9) | 7.6 (4.9; 10.8) | −0.2 (− 0.3; − 0.1) | 2 × 10−5 | 0.001 |
| BIGTT-Sia | 9.7 ± 4.1 | 9.4 ± 4.1 | 9.3 ± 4.0 | 9.0 ± 4.0 | 8.8 ± 4.0 | −0.02 (− 0.03; − 0.01) | 4 × 10−7 | 4 × 10−7 |
| Disposition Index | 304 (211; 447) | 291 (200; 410) | 298 (203; 419) | 297 (205; 412) | 306 (206; 415) | −0.2 (− 0.3; − 0.05) | 0.004 | 0.02 |
Data are from the Inter99 cohort (n = 5631) and are presented as mean ± standard deviation or median (inter quartile range) for each quintile of PRAL score as a description of the cohort. Effect sizes (95% confidence interval) are calculated using linear models with PRAL score as a continuous variable and are given as percentage increase for a one unit increase in PRAL score except for variables that have not been transformed by the natural logarithm in which case it is given as an increase per unit. The linear regression model 1 was adjusted for age, sex, smoking, physical activity and fat, energy and carbohydrate intake. The linear regression model 2 was further adjusted for BMI. BIGTT-Si was not adjusted for sex as this variable is included in the calculation of BIGTT-Si. Calculations of measures of beta cell function and insulin sensitivity were carried out as described in methods. Variables were transformed by the natural logarithm unless otherwise indicated by (a). Quintile values are raw data and are for descriptive purposes only
Associations in the Inter99 study between PRAL score and diabetes-related intermediary traits stratified by sex as well as means and medians for the individual quintiles
| Variable | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | BetaModel 1 (95%CI) |
|
|
|---|---|---|---|---|---|---|---|---|
| Men | ||||||||
| PRAL range (mEq/d) | − 92; −11 | −11; −1 | −1; 6 | 6; 15 | 15; 90 | |||
| HBA1C (%)a | 6.0 ± 0.6 | 5.9 ± 0.6 | 5.9 ± 0.4 | 5.9 ± 0.7 | 5.9 ± 0.6 | − 0.001 (− 0.003; 6 × 10− 5) | 0.06 | 0.04 |
| Plasma glucose (mmol/l) | ||||||||
| Fastinga | 5.8 ± 1.0 | 5.7 ± 0.9 | 5.7 ± 0.7 | 5.7 ± 1.1 | 5.6 ± 0.9 | − 0.001 (− 0.004; 0.0008) | 0.2 | 0.1 |
| 30 mina | 9.5 ± 2.1 | 9.1 ± 1.9 | 9.2 ± 1.8 | 9.2 ± 1.8 | 9.0 ± 1.8 | −0.003 (− 0.007; 0.001) | 0.2 | 0.09 |
| 120 min | 5.6 (4.6; 7.0) | 5.9 (4.9; 6.9) | 5.9 (4.8; 6.9) | 5.7 (4.8; 6.79) | 5.9 (4.9; 7.0) | 0.2 (0.1; 0.3) | 3 × 10− 6 | 6 × 10− 6 |
| Serum insulin (pmol/l) | ||||||||
| Fasting | 34 (23; 52) | 36 (24; 54) | 38 (25; 56) | 37 (25; 57) | 37 (25; 55) | 0.2 (0.02; 0.3) | 0.02 | 0.052 |
| 30 min | 244 (170; 356) | 251 (165; 368) | 255 (181; 380) | 253 (173; 382) | 264 (185; 396) | 0.06 (−0.08; 0.2) | 0.4 | 0.9 |
| 120 min | 123 (67; 223) | 141 (82; 233) | 155 (83; 255) | 143 (81; 242) | 150 (89; 275) | 0.6 (0.4; 0.8) | 4 × 10−9 | 5 × 10−9 |
| Measures of beta cell function | ||||||||
| Insulinogenic index | 22.5 (15.0; 34.0) | 23.5 (15.2; 34.9) | 23.8 (16.2; 35.5) | 23.1 (15.5; 36.3) | 25.6 (16.6; 38.8) | 0.08 (−0.09; 0.2) | 0.3 | 0.6 |
| Corrected insulin response | 511 (306; 820) | 557 (358; 932) | 564 (353; 968) | 563 (360; 891) | 655 (384; 1008) | 0.1 (−0.04; 0.3) | 0.1 | 0.2 |
| Measures of insulin sensitivity | ||||||||
| HOMA-IR | 1.5 (0.9; 2.3) | 1.5 (1.0; 2.3) | 1.6 (1.0; 2.4) | 1.6 (1.0; 2.4) | 1.5 (1.0; 2.4) | 0.1 (−0.02; 0.3) | 0.09 | 0.2 |
| ISIMatsuda | 7.7 (4.9; 11.5) | 7.3 (4.9; 11.1) | 7.2 (4.8; 10.6) | 7.1 (5.0; 11.0) | 7.4 (4.6; 10.6) | −0.2 (−0.3; − 0.03) | 0.02 | 0.04 |
| BIGTT-Sia | 8.3 ± 3.6 | 8.1 ± 3.5 | 8.0 ± 3.4 | 8.1 ± 3.5 | 8.1 ± 3.6 | −0.02 (− 0.02; − 0.007) | 3 × 10−4 | 3 × 10−4 |
| Disposition Index | 285 (188; 407) | 273 (185; 390) | 277 (188; 381) | 282 (186; 382) | 302 (197; 419) | −0.1 (− 0.3; 0.05) | 0.2 | 0.3 |
| Women | ||||||||
| PRAL range (mEq/d) | −84; −15 | −15; −5 | −5; 1 | 1; 9 | 9; 77 | |||
| HBA1C (%)a | 5.8 ± 0.8 | 5.7 ± 0.4 | 5.7 ± 0.4 | 5.7 ± 0.5 | 5.7 ± 0.5 | −0.0002 (−0.001; 0.0009) | 0.7 | 0.3 |
| Plasma glucose (mmol/l) | ||||||||
| Fastinga | 5.4 ± 0.7 | 5.3 ± 0.5 | 5.3 ± 0.5 | 5.3 ± 0.6 | 5.3 ± 0.9 | 0.001 (−0.0005; 0.003) | 0.2 | 0.4 |
| 30 mina | 8.1 ± 1.8 | 8.2 ± 1.7 | 8.1 ± 1.7 | 8.1 ± 1.8 | 8.2 ± 1.7 | 0.003 (− 0.002; 0.007) | 0.3 | 0.8 |
| 120 min | 5.7 (4.9; 6.7) | 5.9 (4.9; 6.9) | 6.0 (5.2; 6.9) | 6.0 (5.1; 7.0) | 6.0 (5.2; 7.1) | 0.2 (0.08; 0.2) | 3 × 10−5 | 7 × 10−4 |
| Serum insulin (pmol/l) | ||||||||
| Fasting | 31 (22; 46) | 30 (22; 44) | 34 (23; 51) | 34 (24; 47) | 33 (24; 50) | 0.3 (0.1; 0.4) | 8 × 10−4 | 0.03 |
| 30 min | 238 (171; 325) | 228 (168; 322) | 238 (178; 324) | 243 (179; 348) | 253 (185; 347) | 0.1 (−0.02; 0.3) | 0.08 | 0.5 |
| 120 min | 155 (104; 230) | 162 (113; 246) | 175 (114; 259) | 178 (119; 277) | 185 (123; 275) | 0.5 (0.4; 0.7) | 1 × 10−8 | 1 × 10−6 |
| Measures of beta cell function | ||||||||
| Insulinogenic index | 25.3 (17.6; 37.4) | 24.4 (17.3; 34.4) | 24.7 (17.8; 35.9) | 26.0 (18.4; 39.5) | 27.1 (18.6; 38.7) | 0.07 (−0.09; 0.2) | 0.4 | 0.8 |
| Corrected insulin response | 736 (483; 1224) | 693 (454; 1131) | 762 (456; 1223) | 775 (494; 1278) | 827 (488; 1352) | 0.05 (−0.2; 0.3) | 0.6 | 0.7 |
| Measures of insulin sensitivity | ||||||||
| HOMA-IR | 1.2 (0.84; 1.8) | 1.2 (0.85; 1.8) | 1.3 (0.89; 2.0) | 1.3 (0.94; 1.9) | 1.3 (0.91; 2.0) | 0.3 (0.1; 0.4) | 8 × 10−4 | 0.04 |
| ISIMatsuda | 8.8 (6.1; 12.1) | 8.7 (6.0; 12.3) | 8.2 (5.4; 11.7) | 8.0 (5.7; 10.9) | 7.9 (5.5; 11.0) | −0.3 (−0.5; −0.2) | 2 × 10−5 | 0.002 |
| BIGTT-Sia | 10.7 ± 4.2 | 10.6 ± 4.1 | 10.3 ± 4.4 | 10.3 ± 4.1 | 10.0 ± 4.3 | −0.03 (− 0.04; − 0.02) | 8 × 10−6 | 8 × 10−6 |
| Disposition Index | 324 (225; 474) | 316 (217; 434) | 308 (204; 425) | 312 (227; 431) | 324 (223; 428) | −0.2 (− 0.4; − 0.08) | 0.003 | 0.02 |
Data are from the Inter99 cohort and presented as mean ± standard deviation or median (inter quartile range) for each quintile of PRAL score as a description of the cohorts. Effect sizes (95% confidence interval) are calculated using linear models with PRAL score as a continuous variable and are given as percentage increase for a one unit increase in PRAL score except for variables that have not been transformed by the natural logarithm in which case it is given as an increase per unit. The linear regression model 1 was adjusted for age, smoking, physical activity and fat, energy and carbohydrate intake. The linear regression model 2 was adjusted for age, BMI, smoking, physical activity and fat, energy and carbohydrate intake except for BIGTT-Si, which was not adjusted for BMI (as this variable is included in the calculation of BIGTT-Si). Calculations of measures of beta cell function and insulin sensitivity were carried out as described in methods. Variables were transformed by the natural logarithm unless otherwise indicated by (a). Quintile values are raw data and are for descriptive purposes only